✦ LIBER ✦

Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer. A randomized trial

✍ Scribed by Rowan T. Chlebowski; Robert Hestorff; Leonard Sardoff; John Weiner; Joseph R. Bateman

Publisher: John Wiley and Sons
Year: 1978
Tongue: English
Weight: 460 KB
Volume: 42
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(197812)42:6<2546::aid-cncr2820420607>3.0.co;2-c

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of advanced colon cancer with

Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil. Prognostic aspects of the differential white blood cell count

✍ Rowan T. Chlebowski; Ivan Silverberg; Thomas Pajak; John Weiner; Carl Kardinal; 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 455 KB

Cyclophosphamide, methotrexate, and 5-fl

Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A southwest oncology group study

✍ Antoinette J. Wozniak; Brent A. Blumenstein; E. David Crawford; Michael Boileau; 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 381 KB 👁 2 views

A prospective, randomized phase III tria

A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma

✍ Cesar Blajman; L. Balbiani; J. Block; F. Coppola; R. Chacon; L. Fein; S. Bonicat 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 1 views

## Background: A prospective, multicenter, randomized, phase iii trial comparing the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide (fac) with a combination of vinorelbine and doxorubicin (na) in the treatment of patients with advanced breast carcinoma w